PT  - JOURNAL ARTICLE
AU  - Sarkar, Rakesh
AU  - Chawla-Sarkar, Mamta
AU  - Majumdar, Swagata
AU  - Lo, Mahadeb
AU  - Chattopadhyay, Shiladitya
TI  - Geographical and temporal distribution of SARS-CoV-2 globally: An attempt to correlate case fatality rate with the circulating dominant SARS-CoV-2 clades
AID  - 10.1101/2021.05.25.21257434
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.05.25.21257434
4099  - http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257434.short
4100  - http://medrxiv.org/content/early/2021/05/27/2021.05.25.21257434.full
AB  - Uncontrolled high transmission is driving the continuous evolution of SARS-CoV-2, leading to the nonstop emergence of the new variants with varying sensitivity to the neutralizing antibodies and vaccines.Wehave analysed of 8,82,740 SARS-CoV-2 genome sequences, collected and sequenced during late December 2019 to 25 March 2021 from all across the world. The findings revealed differences in temporal and spatial distribution,and predominance of various clades/variants among six different continents.We found no clear association between the pathogenic potential of the various clades by comparing the case fatality rate (CFR) of 170 countries with the predominant SARS-CoV-2 clades in those countries, demonstrating the insignificance of the clade specific mutations on case fatality. Overall, relying on a large-scale dataset,this study illustratedthe time-basedevolution andprevalence of various clades/variantsamong different geographic regions.The study may help in designing continent specific vaccines in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis is an independent study and not supported by any funding agency.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This manuscript used freely available sequencing data from global initiative of sharing all influenza data (GISAID) (https://www.gisaid.org/), and does not involve any human subjects.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll sequence data analyzed were freely available at the global initiative of sharing all influenza data (GISAID) (https://www.gisaid.org/)